SCHEMBL755167

SCHEMBL755167

COc1ccc(Oc2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.83
HPGD P15428 1/20 0.83
RAB9A P51151 1/20 0.83
PARP10 Q53GL7 2/20 0.68
CES2 O00748 2/20 0.61
CES1 P23141 2/20 0.61
CA1 P00915 5/20 0.59
CA2 P00918 5/20 0.59
PARP1 P09874 1/20 0.57
PARP2 Q9UGN5 1/20 0.57
PARP4 Q9UKK3 1/20 0.57
LTA4H P09960 2/20 0.56
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
PLK1 P53350 1/20 0.53
ESRRA P11474 1/20 0.53
BACE1 P56817 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13599772 1.00 MAPT (0.83) MAPTHPGDRAB9APARP10CES2
SCHEMBL14407940 0.94 MAPT (0.73) MAPTHPGDRAB9APARP10CES2
SCHEMBL14407928 0.94 MAPT (0.73) MAPTHPGDRAB9APARP10CES2
SCHEMBL14198677 0.94 MAPT (0.73) MAPTHPGDRAB9APARP10CES2
SCHEMBL12372656 0.94 MAPT (0.73) MAPTHPGDRAB9APARP10CES2
SCHEMBL12372650 0.94 MAPT (0.73) MAPTHPGDRAB9APARP10CES2
P-Methoxy-Acetophenone SCHEMBL41285 0.93 MAPT (0.70) MAPTHPGDRAB9APARP10CES2
Mequinol SCHEMBL5836060 0.92 MAPT (0.70) MAPTHPGDRAB9APARP10CES2
P-Methoxy-Acetophenone SCHEMBL27841741 0.91 MAPT (0.67) MAPTHPGDRAB9APARP10CES2
P-Methoxy-Acetophenone SCHEMBL27814658 0.91 MAPT (0.67) MAPTHPGDRAB9APARP10CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368595-A1 NOVEL MOLECULES Xeniopro GmbH (DE) 2025-12-04 US claimed
CN-115697053-A Biocide composition 巴斯夫欧洲公司 2023-02-03 CN claimed
US-20250368595-A1 NOVEL MOLECULES Xeniopro GmbH (DE) 2025-12-04 US disclosed
US-20230141913-A2 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY Xeniopro GmbH (DE) 2023-05-11 US disclosed
CN-116018138-A Substituted 1H-imidazo [1,2-b ] pyrazole-3-carboxamides as inhibitors of brunauer tyrosine kinase 河南知微生物医药有限公司 2023-04-25 CN disclosed
US-20220411430-A1 SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) 2022-12-29 US disclosed
US-20220249500-A1 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY Xeniopro GmbH (DE) 2022-08-11 US disclosed
WO-2022118186-A1 SENOTHERAPEUTIC COMPOUND BIONEXA S.R.L. (IT) 2022-06-09 WO disclosed
WO-2022012550-A1 SUBSTITUTED 1H-IMIDAZO [1, 2-B] PYRAZOLE-3-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS HENAN NORMAL UNIVERSITY (CN) 2022-01-20 WO disclosed
EP-3326715-B1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE CE PHARM CO LTD (CN) 2021-09-15 EP disclosed
WO-2021110142-A1 SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS HENAN NORMAL UNIVERSITY (CN) 2021-06-10 WO disclosed
EP-1254101-A1 PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY Novo Nordisk A/S (DK) 2002-11-06 EP disclosed
WO-2001055085-A1 PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY NOVO NORDISK A/S (DK) 2001-08-02 WO disclosed
EP-0970084-A1 PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-01-12 EP disclosed
US-6001839-A Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors BASF AKTIENGESELLSCHAFT (DE) 1999-12-14 US disclosed
WO-1998041525-A1 PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1998-09-24 WO disclosed
EP-0324472-B1 KETENEDITHIOACETAL DERIVATIVES AND PROCESSES FOR PRODUCING THE SAME AS WELL AS A COMPOSITION CONTAINING THE SAME NIHON NOHYAKU CO., LTD. (JP) 1992-09-02 EP disclosed
US-5098928-A Antilipemic agents and treatment of arteriosclerosis NIHON NOHYAKU CO., LTD. (JP) 1992-03-24 US disclosed
EP-0324472-A2 Ketenedithioacetal derivatives and processes for producing the same as well as a composition containing the same NIHON NOHYAKU CO., LTD. (JP) 1989-07-19 EP disclosed
US-4536517-A ANTIDIABETIC, ANTILIPEMIC AGENTS AMERICAN CYANAMID COMPANY (US) 1985-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249500-A1 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY AHR, MUSK, TYR MAPT 4044/4885HPGD 1353/4885RAB9A 2351/4885
US-20250368595-A1 NOVEL MOLECULES MUSK, IKZF3, TYR MAPT 3885/4885HPGD 2438/4885RAB9A 2783/4885
US-20230141913-A2 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY AHR, MUSK, TYR MAPT 4044/4885HPGD 1353/4885RAB9A 2351/4885
US-20220411430-A1 SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS BTK, SYK, LYN MAPT 4308/4885HPGD 3784/4885RAB9A 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.